Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma.

Molecular cancer - 4 Jul 2024

Park Byung-Sun, Jeon Heeju, Kim Yeonseo, Kwon Haejin, Choi Ga-Eun, Chi Sung-Gil, Park Hyun-Mee, Lee Hyunbeom, Kim Tackhoon

Abstract excerpt

BACKGROUND: BRAF inhibitors are widely employed in the treatment of melanoma with the BRAF V600E mutation. However, the development of resistance compromises their therapeutic efficacy. Diverse genomic and transcriptomic alterations are found in BRAF inhibitor resistant melanoma, posing a pressing need for convergent, druggable target that reverse therapy resistant tumor with different resistance mechanisms....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Lysine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Peptide Initiation Factors

Share to Polyamines

Share to Proto-Oncogene Proteins c-myc

Share to RNA-Binding Proteins

Share to Vemurafenib

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38965534
DOI: 10.1186/s12943-024-02031-w
PMCID: PMC11223307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma.PMID 38965534Read ↗

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.Semantic proximity Read ↗

Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAF <sup>V600</sup> melanomaSemantic proximity Read ↗

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.Semantic proximity Read ↗

Proteogenomic Characterization Reveals Therapeutic Opportunities Related to Mitochondrial Function in MelanomaSemantic proximity Read ↗

The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.Semantic proximity Read ↗

Wild-type IDH1 inhibition enhances chemotherapy response in melanoma.Semantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

A methyl-to-acetyl switch in H3K27 drives metabolic reprogramming and resistance to BRAFV600E inhibition in melanoma.Semantic proximity Read ↗

Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma.Semantic proximity Read ↗

Identification of pathways modulating Vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screenSemantic proximity Read ↗

Relationship between melanoma vemurafenib tolerance thresholds and metabolic pathway choice and Wnt signaling involvementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.